Evaluating Enhanced Recovery After Surgery for Pituitary Tumor Patients
To Assess the Impact of the Enhanced Recovery After Surgery (ERAS) Consensus on the Effectiveness and Prognosis of Patients With Endoscopic Pituitary Tumor Surgery
This study is testing whether following a special recovery plan after surgery helps people with pituitary tumors heal better and faster.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 70 (estimated) |
| Ages | 20 Years to 75 Years |
| Sex | All |
| Sponsor | Chang Gung Memorial Hospital Academic / other |
| Locations | 1 site (Kaohsiung) |
| Trial ID | NCT06221020 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the effectiveness of Enhanced Recovery After Surgery (ERAS) protocols in patients undergoing surgery for pituitary gland tumors. It focuses on various aspects of the ERAS approach, including pre-operative and post-operative rehabilitation, pain management, and early resumption of activities. By comparing outcomes between patients who follow the ERAS protocol and those who do not, the study seeks to identify which elements of ERAS contribute most significantly to patient recovery and safety. The findings will help enhance medical practices related to pituitary tumor management.
Who should consider this trial
Good fit: Ideal candidates include individuals clinically diagnosed with pituitary tumors who can provide informed consent.
Not a fit: Patients with other malignant tumors, severe infections, or those who are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved recovery times and reduced complications for patients undergoing pituitary tumor surgery.
How similar studies have performed: Other studies have shown positive outcomes with ERAS protocols in various surgical contexts, suggesting potential success in this application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical diagnosis of pituitary tumors * To sign a written informed consent form Exclusion Criteria: * Diagnosed with other malignant tumors * Severe infections, such as osteomyelitis, acute inflammation at the affected site, or open wounds at the treatment area * Pregnant women * Coagulation disorders or those taking anticoagulant medication * Other central nervous system disorders, alcohol addiction, other addictive drugs, or mental illness that may affect clinical assessment * Deemed unsuitable for surgical treatment or unable to comply with clinical evaluation upon assessment
Where this trial is running
Kaohsiung
- Kaohsiung Chang Gung Memorial Hospital — Kaohsiung, Taiwan (Recruiting)
Study contacts
- Principal investigator: Hung-Chen Wang, MD, PhD — Chang Gung Memorial Hospital
- Study coordinator: Hung-Chen Wang, MD, PhD
- Email: m82whc@gmail.com
- Phone: +886-975056287
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.